Citations

Showing 10 of 108152 citations.

3D Printing‐Enabled Nanoparticle Alignment: A Review of Mechanisms and Applications
Ravichandran, Dharneedar , Kakarla, Mounika , Nian, Qiong , Azeredo, Bruno , Jin, Kailong , Cornella, Jeffrey L. , Miquelard‐Garnier, Guillaume , Song, Kenan , Song, Kenan , Ravichandran, Dharneedar , Xu, Weiheng , Jambhulkar, Sayli , Zhu, Yuxiang , Chen, Xiangfan , Vernon, Brent L. , Lott, David G. , Shefi, Orit , Yang, Yang

Mayo Clinic

Small | June 27, 2021 | Volume: 17 | Issue: 45 | Pages: No page available

10.1002/smll.202100817 | PMID 34176201 Get It

Abstract3D printing (additive manufacturing (AM)) has enormous potential for rapid tooling and mass production due to its design flexibility and significant reduction of the timeline from design to manufacturing. The current state‐of‐the‐art in 3D printing focuses on material manufacturability and engineering applications. However, there still exists the bottleneck of low printing resolution and processing rates, especially when nanomaterials need tailorable orders at different scales. An interesting phenomenon is the preferential alignment of nanoparticles that enhance material properties. Therefore, this review emphasizes the landscape of nanoparticle alignment in the context of 3D printing. Herein, a brief overview of 3D printing is provided, followed by a comprehensive summary of the 3D printing‐enabled nanoparticle alignment in well‐established and in‐house customized 3D printing mechanisms that can lead to selective deposition and preferential orientation of nanoparticles. Subsequently, it is listed that typical applications that utilized the properties of ordered nanoparticles (e.g., structural composites, heat conductors, chemo‐resistive sensors, engineered surfaces, tissue scaffolds, and actuators based on structural and functional property improvement). This review's emphasis is on the particle alignment methodology and the performance of composites incorporating aligned nanoparticles. In the end, significant limitations of current 3D printing techniques are identified together with future perspectives.
The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial
Parlow, Simon , Santo, Pietro Di , Mathew, Rebecca , Jung, Richard G. , Gillmore, Taylor , Mao, Brennan, Abdel‐Razek, Omar , Ramirez, F. Daniel , Dick, Alexander , Glover, Christopher, Russo, Juan , Froeschl, Michael , Labinaz, Marino , Hibbert, Benjamin , investigators, the CAPITAL DOREMI, Ramirez, F Daniel , Hibbert, Benjamin , Simard, Trevor , Marbach, Jeffrey A. , Fernando, Shannon M. , investigators, the CAPITAL DOREMI

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | June 27, 2021 | Volume: 10 | Issue: 7 | Pages: 712-720

10.1093/ehjacc/zuab052 | PMID 34382063 Get It

AbstractAimsCardiogenic shock (CS) is a state of low cardiac output resulting in end-organ hypoperfusion. Despite high in-hospital mortality rates, little evidence exists regarding the optimal mean arterial pressure (MAP) target in CS. We therefore evaluated the relationship between achieved MAP and clinical outcomes in patients with CS.Methods and resultsWe performed a post hoc analysis of the CAPITAL DOREMI trial: a randomized, double-blind trial comparing dobutamine to milrinone in patients with CS. We divided patients into a high MAP group (average MAP ≥ 70 mmHg over the 36 h following randomization), and a low MAP group (average MAP < 70 mmHg). Our primary outcome included in-hospital all-cause mortality, resuscitated cardiac arrest, need for cardiac transplantation or mechanical circulatory support, non-fatal myocardial infarction, transient ischaemic attack or stroke, or initiation of renal replacement therapy. In total, 71 (37.0%) patients achieved an average MAP < 70 mmHg, and 121 (63.0%) achieved an average MAP ≥ 70 mmHg. The primary outcome occurred in 48 (67.6%) patients in the low MAP group and 51 (42.2%) patients in the high MAP group [adjusted relative risk (aRR) 0.70; 95% confidence interval (CI) 0.53–0.92; P = 0.01]. All-cause mortality occurred in 41 (57.8%) and 35 (28.9%) patients in the low and high MAP groups, respectively (aRR 0.56; 95% CI 0.40–0.79; P < 0.01). There were no significant differences in any secondary outcomes between each group.ConclusionsIn patients with CS treated with inotrope therapy, low MAP is associated with worse clinical outcomes. Randomized data evaluating optimal MAP targets in CS is needed to guide medical therapy.
Successful Outcomes of Critically Ill Patients with Extreme Metabolic Acidosis Treated with Structured Approach: Case Series
Dragić, Saša , Momčićević, Danica , Zlojutro, Biljana , Jandrić, Milka , Kovačević, Tijana , Djajić, Vlado , Kovačević, Peđja , Gajic, Ognjen

Mayo Clinic

Clinical Medicine Insights: Case Reports | June 27, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/11795476211025138 | PMID 34248359 Get It

Introduction: Hydrogen ion concentration which is expressed as pH value is in human blood maintained in narrow physiological range (7.36-7.44 in arterial blood). This range is crucial for normal functioning of most biochemical reactions. Extreme acidosis with pH < 6.8 is incompatible with life, unless pathophysiologic process is rapidly reversed. Timely, standardized, and structured approach to assessment and management of extreme critical illness is essential to maximize the chances of patient’s survival. Cases: We present a series of 3 critically ill patients admitted to Medical intensive care unit (MICU) diagnosed with extreme metabolic acidosis (pH ⩽ 6.8). Each patient was treated using Checklist for Early Recognition and Treatment of Acute Illness and INjury (CERTAIN) which is a standard decision support tool in our MICU. Causes of extreme metabolic acidosis included hemorrhagic shock, sepsis, and acute renal failure and diabetic ketoacidosis. Rapid assessment, prompt resuscitation (IV fluids, vasopressors, mechanical ventilation, and renal replacement), and application of specific causal treatment led to positive outcomes in all 3 patients. Discussion: Medical physiology textbooks set the lower limit of pH value at which life is possible to 6.8. However, examples from clinical practice show that if adequate resuscitation measures are taken early in the acute phase of the disease, the biochemical cascade of reactions that are considered irreversible (at pH ⩽ 6.8) may be reversed after all. Conclusion: Critical care approach to extreme metabolic acidosis is a prime example of applied clinical physiology where basic science and clinical practice connect. With these case series we show that timely and structured approach to critical illness shifts the boundaries of reversibility for some of the most severe physiologic derangements.
Stethoscope – An essential diagnostic tool or a relic of the past?
Qamar, Shahraz , Tekin, Aysun , Taweesedt, Pahnwat , Varón, Joseph , Kashyap, Rahul , Surani, Salim , Taweesedt, Pahnwat Tonya , Kashyap, Rahul , Surani, Salim , Tekin, Aysun

Mayo Clinic

Hospital Practice | June 26, 2021 | Volume: 49 | Issue: 4 | Pages: 240-244

10.1080/21548331.2021.1949170 | PMID 34180345 Get It

Anterior Nucleus of the Thalamus Deep Brain Stimulation with Concomitant Vagus Nerve Stimulation for Drug-Resistant Epilepsy
Parisi, Veronica , Kerezoudis, Panagiotis , Zermeno, Juan Luis Alcala, Gompel, Jamie J. Van , Lundstrom, Brian Nils, Alcala Zermeno, Juan Luis, Van Gompel, Jamie J , Lundstrom, Brian N. , Worrell, Gregory A.

Mayo Clinic

Neurosurgery | June 26, 2021 | Volume: 89 | Issue: 4 | Pages: 686-694

10.1093/neuros/nyab253 | PMID 34333659 Get It

Abstract BACKGROUND The Food and Drug Administration approved the deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) as an adjunctive therapy for drug-resistant epilepsy (DRE) in the United States in 2018. The DBS Therapy for Epilepsy Post-Approval Study is further evaluating the safety and effectiveness of ANT-DBS among different patients’ groups. For this study, devices for vagus nerve stimulation (VNS) must be removed prior to enrolment. OBJECTIVE To investigate the outcomes of concomitant ANT-DBS and VNS treatment for DRE. METHODS A retrospective analysis was performed for 33 patients who underwent ANT-DBS using previous VNS to define distinct subgroups: standard ANT-DBS (9 subjects), ANT-DBS with functional VNS (12 subjects), and ANT-DBS with the VNS implantable pulse generator explanted or turned off at the time of the DBS (12 subjects). Effectiveness and safety data were analyzed across the whole population and among subgroups. RESULTS A mean decrease in seizure frequency of 55% was observed after a mean follow-up of 25.5 mo. Approximately 67% of patients experienced ≥50% reduction in seizure frequency. Seizure reduction percentage was not significantly different among groups. Approximately 50% of subjects with no appreciable improvement and 75% of those who showed benefit after VNS (including improvement in seizure frequency, seizure severity, and seizure duration or quality of life) achieved a seizure reduction ≥50% after ANT-DBS surgery. There were no complications related to concomitant VNS and ANT-DBS. CONCLUSION ANT-DBS for DRE provides excellent results despite previous and ongoing VNS therapy. Removal of VNS does not appear to be necessary before ANT-DBS.
Technical Note: Multiple energy extraction techniques for synchrotron‐based proton delivery systems may exacerbate motion interplay effects in lung cancer treatments
Younkin, James E. , Morales, Danairis Hernandez, Shen, Jiajian , Ding, Xiaoning, Stoker, J. , Yu, Nathan Y. , Daniels, T.B., Fatyga, M., Stoker, Joshua B., Daniels, Thomas B, Bues, Martin , Fatyga, Mirek, Schild, Steven E. , Shen, Jiajian , Sio, Terence T. , Liu, Wei

Mayo Clinic

Medical Physics | June 26, 2021 | Volume: 48 | Issue: 9 | Pages: 4812-4823

10.1002/mp.15056 | PMID 34174087 Get It

Abstract Purpose The multiple energy extraction (MEE) delivery technique for synchrotron‐based proton delivery systems reduces beam delivery time by decelerating the beam multiple times during one accelerator spill, but this might cause additional plan quality degradation due to intrafractional motion. We seek to determine whether MEE causes significantly different plan quality degradation compared to single energy extraction (SEE) for lung cancer treatments due to the interplay effect. Methods Ten lung cancer patients treated with IMPT at our institution were nonrandomly sampled based on a representative range of tumor motion amplitudes, tumor volumes, and respiratory periods. Dose‐volume histogram (DVH) indices from single‐fraction SEE and MEE four‐dimensional (4D) dynamic dose distributions were compared using the Wilcoxon signed‐rank test. Distributions of monitor units (MU) to breathing phases were investigated for features associated with plan quality degradation. SEE and MEE DVH indices were compared in fractionated deliveries of the worst‐case patient treatment scenario to evaluate the impact of fractionation. Results There were no clinically significant differences in target mean dose, target dose conformity, or dose to organs‐at‐risk between SEE and MEE in single‐fraction delivery. Three patients had significantly worse dose homogeneity with MEE compared to SEE (single‐fraction mean D 5% ‐D 95% increased by up to 9.6% of prescription dose), and plots of MU distribution to breathing phases showed synchronization patterns with MEE but not SEE. However, after 30 fractions the patient in the worst‐case scenario had clinically acceptable target dose homogeneity and coverage with MEE (mean D 5% –D 95% increased by 1% compared to SEE). Conclusions For some patients with breathing periods close to the mean spill duration, MEE resulted in significantly worse single‐fraction target dose homogeneity compared to SEE due to the interplay effect. However, this was mitigated by fractionation, and target dose homogeneity and coverage were clinically acceptable after 30 fractions with MEE.
Recurrent Chromosomal Abnormalities in Tissues Involved by Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pearce, Kathryn E., Shi, Min , Peterson, Jess F. , Shi, Min , Peterson, Jess F , Horna, Pedro , Ketterling, Rhett P.

Mayo Clinic

American Journal of Clinical Pathology | June 26, 2021 | Volume: 157 | Issue: 2 | Pages: 286-292

10.1093/ajcp/aqab128 | PMID 34528680 Get It

Abstract Objectives Prognostically relevant chromosomal abnormalities in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are routinely identified by fluorescence in situ hybridization (FISH) on peripheral blood or bone marrow specimens. We studied the prevalence of chromosomal abnormalities on extramedullary tissues involved by CLL/SLL and evaluated their association with prominent proliferation centers (PPCs). Methods FISH for recurrent abnormalities in CLL/SLL was performed on formalin-fixed, paraffin-embedded biopsy sections. PPCs were identified on H&E-stained sections. Available FISH results on peripheral blood or bone marrow specimens were also reviewed. Results Recurrent FISH abnormalities were detected in 69% of 320 CLL/SLL biopsy specimens studied, including +12 (35%), 13q– (24%), 11q– (15%), 17p– (6%), 6q– (2%), and IGH/BCL2 (0.9%). Forty-three patients had abnormal blood or bone marrow FISH analyses, of whom 7 (16%) had discordant +12 and/or 13q–, and 3 (7%) had discordant 17p– or 11q–. Morphology was positive (17%), negative (78%), or equivocal (6%) for PPCs on 247 evaluable biopsy specimens, a finding not significantly associated with FISH results (P = .7). Conclusions Trisomy 12 is overrepresented in tumoral CLL/SLL involvement, compared with the known predominance of 13q– in blood. Discrepancies between leukemic and tissue FISH findings are occasionally encountered. FISH results do not correlate with the presence of PPCs.
Building clinically relevant outcomes across the Alzheimer's disease spectrum
Wessels, Alette M. , Berger, Anna‐Karin , Edgar, Chris J. , Gold, Michael , Miller, David S. , Randolph, Christopher , Ryan, J. Michael, Wunderlich, Glen , Zoschg, Megan Canniere, Trépel, Dominic , Staffaroni, Adam M. , Bain, Lisa J. , Carrillo, María C. , Weber, Christopher J., Rentz, Dorene M. , Annapragada, Ananth , Miller, David S., Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | June 26, 2021 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/trc2.12181 | PMID 34195350 Get It

Abstract Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer's Association Research Roundtable (AARR) meetings, there remains no consensus as to what constitutes a “clinically meaningful outcome” in the eyes of patients, clinicians, care partners, policymakers, payers, and regulatory bodies. Furthermore, the field has not come to agreement as to what constitutes a clinically meaningful treatment effect at each stage of disease severity. The AARR meeting on November 19–20, 2019, reviewed current approaches to defining clinical meaningfulness from various perspectives including those of patients and care partners, clinicians, regulators, health economists, and public policymakers. Participants discussed approaches that may confer clinical relevance at each stage of the disease continuum and fostered discussion about what should guide us in the future.
Outcomes of patients with invasive mucinous and tubular carcinomas of the breast
Huang, Kai , Misra, Subhasis , Gabriel, Emmanuel , Gabriel, Emmanuel M , Bagaria, Sanjay P.

Mayo Clinic

The Breast Journal | June 26, 2021 | Volume: 27 | Issue: 9 | Pages: 691-699

10.1111/tbj.14268 | PMID 34173285 Get It